Arcellx Inc.
Arcellx Reports Third Quarter 2025 Financial Results
Summary
On November 5, 2025, Arcellx, Inc. announced its financial results for the third quarter ended September 30, 2025, revealing a net loss of $55.8 million compared to $25.9 million in the same period of 2024. The company reported collaboration revenue of $4.9 million, down from $26.0 million in 2024, primarily due to the completion of dosing and manufacturing in the iMMagine-1 trial. Research and development expenses decreased slightly, while general and administrative expenses increased, driven by commercial readiness and personnel costs. Arcellx anticipates its cash position will fund operations into 2028.
Profitelligence Alerts
Get alerts for ACLX
Be first to know when Arcellx Inc. files with the SEC.
Filing Categories
Advertisement
About Arcellx Inc.
Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to harness the power of the immune system through its proprietary D-Domain technology platform, which is designed to improve the efficacy and safety of cell-based treatments. Arcellx focuses on targeting malignant cells with precision, thereby enhancing therapeutic outcomes and minimizing adverse effects. Operating within the highly complex and rapidly evolving biotechnology sector, Arcellx significantly contributes to advancements in life sciences and medical treatments. Given its commitment to pioneering scientific discoveries, the company represents a significant player in the push towards personalized medicine and novel cancer therapies. Through collaboration with academic institutions and strategic partnerships, Arcellx endeavors to accelerate the development and commercialization of its pipeline products, aiming to bring life-changing treatments to patients worldwide. Its research-intensive approach and focus on addressing unmet medical needs position Arcellx as an impactful entity in the biopharmaceutical landscape.
Official SEC Documents
Advertisement